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Abstract
Background: We simulated tobacco control and pharmacological strategies for preventing cardiovascular deaths in India,
the country that is expected to experience more cardiovascular deaths than any other over the next decade.
Methods and Findings: A microsimulation model was developed to quantify the differential effects of various tobacco
control measures and pharmacological therapies on myocardial infarction and stroke deaths stratified by age, gender, and
urban/rural status for 2013 to 2022. The model incorporated population-representative data from India on multiple risk
factors that affect myocardial infarction and stroke mortality, including hypertension, hyperlipidemia, diabetes, coronary
heart disease, and cerebrovascular disease. We also included data from India on cigarette smoking, bidi smoking, chewing
tobacco, and secondhand smoke. According to the model’s results, smoke-free legislation and tobacco taxation would likely
be the most effective strategy among a menu of tobacco control strategies (including, as well, brief cessation advice by
health care providers, mass media campaigns, and an advertising ban) for reducing myocardial infarction and stroke deaths
over the next decade, while cessation advice would be expected to be the least effective strategy at the population level. In
combination, these tobacco control interventions could avert 25% of myocardial infarctions and strokes (95% CI: 17%–34%)
if the effects of the interventions are additive. These effects are substantially larger than would be achieved through aspirin,
antihypertensive, and statin therapy under most scenarios, because of limited treatment access and adherence;
nevertheless, the impacts of tobacco control policies and pharmacological interventions appear to be markedly synergistic,
averting up to one-third of deaths from myocardial infarction and stroke among 20- to 79-y-olds over the next 10 y.
Pharmacological therapies could also be considerably more potent with further health system improvements.
Conclusions: Smoke-free laws and substantially increased tobacco taxation appear to be markedly potent population
measures to avert future cardiovascular deaths in India. Despite the rise in co-morbid cardiovascular disease risk factors like
hyperlipidemia and hypertension in low- and middle-income countries, tobacco control is likely to remain a highly effective
strategy to reduce cardiovascular deaths.
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Introduction
The burden of cardiovascular disease (CVD) is rapidly rising in
low- and middle-income countries (LMICs) [1]. LMICs now
account for over three-quarters of all global deaths from heart
disease and stroke [2], with India expected to contribute more
than any other nation to the growth in these deaths over the
decade from 2010 to 2020. More than one in three CVD deaths in
India are projected to occur among young and working-age
people, leading to substantial economic and societal costs [3]. The
United Nations 2011 High Level Meeting on Prevention and
Control of Non-Communicable Diseases identified tobacco use as
a key risk factor for noncommunicable diseases [4,5]. Tobacco-
related deaths are projected to double in LMICs between 2000
and 2030 [1]. Smoking has been estimated to be responsible for
about one in 20 deaths among Indian women and one in five
deaths among Indian men aged 30 to 69 y [6], many due to CVD.
Due in part to tobacco use, CVD deaths are expected to increase
approximately 12% over the next decade [5].
Recognizing the burden of disease attributable to tobacco and
the cost-effectiveness of tobacco control measures [4], India and
175 other countries ratified the World Health Organization
(WHO) Framework Convention on Tobacco Control (FCTC) [7].
The FCTC commits nations to enact tobacco control legislation
fulfilling minimum standards for the production, sale, distribution,
advertisement, and taxation of tobacco, as well as legislation
protecting populations from secondhand smoke [7]. Major FCTC
provisions include smoke-free laws, brief cessation advice by health
care providers, mass media campaigns, a tobacco advertising ban,
and increased tobacco taxes.
Several questions have been recently raised, however, about the
effectiveness of tobacco control measures in LMICs. It remains
unclear how tobacco control will affect future CVD in the setting
of emerging co-morbid factors such as hypertension, obesity, and
diabetes (the concern being that tobacco control efforts could have
diminishing returns in the context of multiple co-morbid risks) [8].
Previous mathematical models of tobacco control have not
accounted for these co-morbid conditions, which pose competing
risks for CVD death [9,10]. Only recently have population-
representative data become available from developing countries
like India, from which we can understand the prevalence rates of
numerous CVD risk factors including smoking, hypertension,
hyperlipidemia, and diabetes, among both urban and rural
populations and among both men and women in multiple age
groups [11].
While India passed national tobacco control legislation in 2003
(the Cigarettes and Other Tobacco Products Act) before it ratified
the FCTC, many of the core FCTC provisions remain poorly
implemented or unenforced. For example, smoke-free legislation
has not been consistently implemented; one in three adults
reported being exposed to smoking at work in 2009 and 2010,
varying from 15.4% in Chandigarh to 67.9% in Jammu and
Kashmir [12]. Tobacco cessation programs have received limited
government financial support, and cessation advice by health care
professionals is provided infrequently [12,13]. Tobacco taxation
remains very low, at around 38% of cigarette and 9% of bidi prices
[14], far below the minimum of 70% the WHO recommends [15].
This paper estimates the impact of implementing key FCTC
policies on CVD mortality in India using a mathematical model to
calculate the number of deaths from myocardial infarction or
stroke among Indian adults over the decade from 2013 through
2022. Moving beyond prior models of tobacco control, our model
incorporates the effects of co-morbid cardiovascular risk factors to
capture complex demographic patterns of concurrent tobacco use
and other key cardiovascular risk factors. Further, we examine
tobacco use in its myriad of forms common in India, not just
cigarette smoking. We also employ new population-representative,
age-stratified data from India on both urban and rural prevalence
rates in risk factors such as systolic blood pressure, total
cholesterol, and diabetes among both men and women. This
approach allows us to estimate the added value of tobacco control
in an era where other major risk factors are also expected to
contribute significantly to CVD mortality.
Methods
Modeling Approach and Underlying Assumptions
We constructed a discrete-time microsimulation model of
myocardial infarction and stroke mortality among Indian residents
aged 20 to 79 y over the decade from 1 January 2013 through 31
December 2022. The model is stratified into 24 cohorts defined by
10-y age groups (20–29, 30–39,…, 70–79 y old), gender, and rural
versus urban location. The model is an extension of a model of
myocardial infarction and stroke mortality developed by the
Institute for Health Metrics and Evaluation [16]; however, the
effect sizes in the model were updated using India-specific data
from 2010 through 2012, as listed in the Text S1. The model
simulates 10,000 individuals for each of the 24 age-, gender-, and
location-specific cohorts. We then generate a ‘‘risk factor profile’’
for each individual in each cohort based on the WHO data listed
in Tables S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11, S12, which
describes the population distribution of major CVD risk factors,
correlations between the risk factors, and the relative risk of
myocardial infarction and stroke mortality conferred by these risk
factors. In other words, each of the 10,000 risk profiles for each
cohort is different, based on age, gender, and location. Age was
simulated as a continuous variable and then divided into cohorts.
Age-, gender-, and location-specific secular trends in risk factor
prevalence and mortality are included, based on the WHO Global
InfoBase 2012 mortality database [17]. The 20 to 79-y-old age
group was chosen because age-specific disaggregated data from
India are available from which to specify their cardiovascular risks
and tobacco use habits. The previous model [16] incorporated
tobacco smoking, blood pressure, cholesterol, diabetes, and
preexisting CVD and cerebrovascular disease, and was used to
estimate worldwide CVD mortality rates; we modified the model
to specifically include several different forms of tobacco use
(specified further below) and capture the unique demographics
and risks of the Indian population.
Six risk factors are incorporated into the risk factor profiles:
systolic blood pressure, total cholesterol, tobacco use, diabetes,
coronary heart disease, and cerebrovascular disease. Tobacco use
is further subdivided into cigarette smoking, bidi (small hand-
rolled cigarette) smoking, chewing tobacco, dual use (both chewing
tobacco and smoking either bidis or cigarettes), secondhand smoke
exposure, and former tobacco use. All of the data on risk factor
prevalence, as well as on the impact of tobacco measures on
cardiovascular risk, were specifically collected from population-
representative, disaggregated surveys from India (Table 1). Body
mass index was not included because, although it is correlated with
blood pressure, cholesterol, and diabetes, it had a small effect size
on myocardial infarctions or strokes when adjusting for the other
risk factors [16].
In each year of the simulation, an individual’s probability of
death from myocardial infarction, stroke, and all-cause mortality
was calculated as a function of that individual’s risk profile, the
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relative risk of disease conferred by each risk factor in their profile,
and their age, gender, and location. The model’s predictions of
deaths were validated against Global Burden of Disease estimates
for myocardial infarction, stroke, and other deaths for the years
2004 and 2008 (the two time points available) (Figure S1).
We ran the model 10,000 times using Monte Carlo sampling
from the risk factor distributions in each cohort, the range of
relative risk estimates used to estimate the probability of death for
each individual, and demographic projection ranges from the
Indian 2011 census to capture demographic uncertainty, gener-
ating 95% confidence intervals around the estimated mean rates of
death from each cause in each cohort. This process included
sampling repeatedly from the uncertainty distributions of the
variables listed in Tables 1 and S1, S2, S3, S4, S5, S6, S7, S8, S9,
S10, S11, S12. The model was implemented in MATLAB version
R2012a (MathWorks).
Full details of the model, including complete equations and
input data, appear in Text S1.
Simulated Interventions
We simulated five tobacco control interventions specified in the
FCTC: (1) smoke-free laws, (2) brief cessation advice by health
providers, (3) mass media campaigns covering channels of
communication such as television, radio, newspapers, billboards,
posters, leaflets, or booklets intended to reach large numbers of
people, (4) a tobacco advertising ban, and (5) increased cigarette
and/or bidi taxes. The effect of each intervention on an
individual’s probability of tobacco use was taken from relevant
Table 1. Model parameters and data sources.
Input Specifications/Value Source
Population size and secular trends Breakdowns by age, gender,
and urban/rural location
Indian census, 2011 [32]
Mortality rates from coronary heart disease,
cerebrovascular disease, and other causes
See Tables S10, S11 India-specific WHO Global Burden of
Disease estimates, 2008 [33]
Population distribution of systolic blood pressure See Tables S1 and S8 India-specific WHO estimates, 2011 [11]
Population distribution of total cholesterol See Tables S2 and S8 India-specific WHO estimates, 2012 [17]
Population distribution of tobacco use (further subdivided
into passive exposure only, former user, cigarette smoking,
bidi smoking, chewing tobacco, and dual use)
See Tables S3 and S8 India-specific data from the Global Adult
Tobacco Survey, 2009–2010 [12]
Diabetes prevalence See Tables S4 and S8 India-specific data from a cross-sectional
survey, 2004 [34], updated using estimates
from a Bayesian analysis of prevalence
trends, 2011 [35]
Coronary heart disease prevalence See Table S5 and S8 India-specific WHO estimates, 2010 [5]
Cerebrovascular disease prevalence See Tables S6 and S8 India-specific WHO estimates, 2010 [18]
Correlation among risk factors listed above See Table S7 India-specific data from the Institute for
Health Metrics and Evaluation, 2007 [16]
Relative risk of coronary heart disease and cerebrovascular
disease conferred by changes in each risk factor listed above
See Table S9 Prior reviews of international data
[16,36,37]
Relative risk reduction of coronary heart disease and cerebrovascular
disease conferred by aspirin, statin, and/or blood pressure treatments
See Table S12 Prior reviews of international data [16,25]
Smoke-free laws: prohibit smoking in workplaces and public places Reduces passive smoking probability
by 64% (95% CI: 39%–89%) and active
smoking probability for both bidis and
cigarettes by 1% (0%–2%)
Systematic reviews and meta-analysis
[22,26,38]
Brief cessation advice by health care providers: standardized motivational
interviewing or cessation advice in primary and secondary care facilities
Reduces active smoking probability for
both bidis and cigarettes by 1%
(95% CI: 0%–3%)
Cochrane review [39]
Mass media campaign: anti-tobacco messaging covering
channels of communication such as television, radio,
newspapers, billboards, posters, leaflets
Reduces active smoking probability for
both bidis and cigarettes by 5%
(95% CI: 1%–11%)
Cochrane review and case study [23,40]
Advertising ban: tobacco product advertising banned in films,
sporting events, TV/radio, and print media
Reduces active smoking probability for
both bidis and cigarettes by 6%
(95% CI: 5%–7%)
National Bureau of Economic Research
[20,41]
Tax increases for bidis 50% tax reduces active bidi smoking
probability by 4% (95% CI: 3%–5%),
300% tax reduces probability by 24%
(95% CI: 22%–26%), and 500% tax reduces
probability by 40% (95% CI: 37%–43%)
International Union Against Tuberculosis
and Lung Disease [14]
Tax increases for cigarettes 50% tax increase reduces active cigarette
smoking probability by 6% (95% CI:
3%–9%), 300% tax increase reduces
probability by 31% (95% CI: 16%–47%),
and 500% tax increase reduces
probability by 52% (95% CI: 26%–78%)
International Union Against Tuberculosis
and Lung Disease [14]
doi:10.1371/journal.pmed.1001480.t001
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international systematic reviews and meta-analyses, summarized in
Table 1. We assumed that India’s populace would react similarly
to these interventions as other international populations; we chose
meta-analyses that incorporated international settings to estimate
intervention effects, as displayed in Table 1. We also developed a
baseline simulation using rates of introduction of interventions
based on real-world experiences [18–20], then performed several
sensitivity analyses in which we varied the degrees of coverage to
examine the impact of a range of possible implementation effects
and timescales (Table 1). In our baseline simulation, we assumed
that legislative interventions would be immediately introduced
with full coverage throughout the country, but subsequent effects
on smoking would occur linearly over a decade and further
cardiovascular effects would also occur gradually over time, as
detailed further below [21,22]. In sensitivity analyses, we estimated
the impact of a gradual introduction of legislation at a linear rate
from 0% to 80% legislative coverage over 5 y, to achieve a steady
state of 80% coverage, the level previously estimated as a target
level for analogous interventions [16].
We varied the efficacy of each intervention around a normal
distribution defined by the 95% confidence intervals given in
Table 1 to characterize the uncertainty in our estimates. In the
case of smoke-free laws, mass media campaigns, and a tobacco
advertising ban, our sensitivity analysis included some low ranges
of potential effectiveness or enforcement (Table 1) to simulate the
potential outcomes when these measures are poorly enforced [18–
20]. We also estimated that the CVD risk reduction benefits of
quitting tobacco smoking would decline at an exponential rate
over 10 y, with a time constant of 19.1 mo, yielding a 15% decline
in risk in the first year, 36% by the end of 3 y, and the remaining
benefits over the subsequent 8 y [21,22].
In the case of taxation, we simulated cigarette and bidi taxation
both individually and concurrently. The impact of taxation on
consumption was calculated in a prior study that estimated the
price elasticity of cigarette consumption (in which a 10% increase
in cigarette prices reduced consumption by 3.4% in rural India
and 1.9% in urban India) and bidi consumption (in which a 10%
rise in bidi price reduced consumption by 9.2% in rural India and
8.5% in urban India) [14]. These estimates assume that all tax
increases are passed on to customers, and do not account for
possible tax evasion or smuggling. The WHO recommends that at
least 70% of the price of a tobacco product be made up by tax,
which would require an approximate 300% increase in the tax
rate on cigarettes in India [23]. We therefore simulated this tax
increase for cigarettes and bidis in our baseline simulation. In
sensitivity analyses, we varied the taxation increase from a 50% to
a 800% increase over existing tax rates. Taxation on bidis would
have to increase approximately 800% to achieve the WHO
recommendation.
Independence and Synergy
In our baseline simulation, we forecast the impact of each
intervention one at a time. We also simulated different degrees of
synergy in the effectiveness of interventions. No studies have
clearly established whether the same or different individuals would
be prevented from tobacco use when these interventions are
combined in India (e.g., if the effects of two interventions
simultaneously may not be purely additive), although some
evidence in other populations suggests that different tobacco
control interventions may have synergy by enhancing the
effectiveness of each intervention when multiple interventions
are combined at the same time [24]. Hence, we conducted a
sensitivity analysis in which we assumed no additive effect among
interventions (i.e., the combined effect of multiple simultaneous
interventions is equal to the effect of the intervention with the
largest effect), an analysis where the effects are cumulative (i.e., the
effect of multiple measures is equal to 12[(12risk reduction from
intervention A)6(12risk reduction from intervention B)6(12risk
reduction from intervention C)], etc.) and an analysis where we
assumed that interventions reinforce each other synergistically by
25% (i.e., using the cumulative equation above, but with a 25%
increase in the individual effectiveness shown in Table 1 of each
intervention when the interventions are combined).
Comparison with Pharmacological Interventions
We compared the effects of tobacco control interventions on
myocardial infarction and stroke deaths with the effects of other
interventions aimed at reducing cardiovascular risk, specifically the
WHO’s proposal to expand pharmacological treatment access to
aspirin, antihypertensive medications, and statins. As described in
Text S1, we sampled from normal distributions constructed from
the 95% confidence intervals around the annual relative risk
reduction for myocardial infarctions and stroke mortality con-
ferred by these medications, and assumed their benefits were
additive, as in prior simulations [16,25]. We examined prior rates
of expansion in access to these medications; penetration of
treatment as primary prevention is below 50% in the UK
National Health Service, for example, after over a decade of
cardiovascular treatment guideline use [4,26]. We simulated that,
optimistically, 45% of the population in India that should receive
treatment with these medications per WHO targets would have
access to them over 10 y, paralleling the UK case. In sensitivity
analyses, we also simulated the WHO target of achieving 80%
treatment access linearly over 10 y (from current coverage
estimates of 15%) [16]. The eligibility for medical treatment and
relative risk reduction for myocardial infarction and stroke
mortality from each type of medication (aspirin, antihypertensive,
and statin treatment) is detailed in Text S1. We include treatment
with an angiotensin-converting enzyme inhibitor and thiazide
diuretic for those without CVD or cerebrovascular disease history,
while including beta-blockers for those with such a history, as per
WHO guidelines further detailed in Text S1 [16,25]. As in prior
simulations, we assumed that persons without a prior history of
coronary heart disease or cerebrovascular disease would have 40%
adherence to the medications (95% CI: 20%–60%, which we
simulated by sampling from a normal distribution), while those
with a coronary heart disease or cerebrovascular disease history
would have 60% adherence (95% CI: 40%–80%, also sampled
from a normal distribution) [16,25]. We simulated the effects of
these medications separately and jointly by assuming their effects
were complementary and therefore additive.
Results
Scenario without Tobacco Control Measures
Without any new interventions between 2013 and 2022, the 20-
to 79-y-old population of India is projected to experience
approximately 21.9 million (95% CI: 16.9 to 26.9 million) deaths
from myocardial infarctions and 14.7 million (95% CI: 13.7 to
15.7 million) deaths from stroke, assuming the continuation of
current trends in age-, gender-, and location-specific CVD risk
factors and mortality rates. Figures 1 and 2 summarize the
predicted overall mortality trend in cardiovascular deaths.
Approximately 33% of the myocardial infarction deaths would
be anticipated among urban men, followed by 31% among rural
men, 19% among urban women, and 17% among rural women.
About 27% of stroke deaths would be expected among urban men,
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25% among rural men, 25% among urban women, and 23%
among rural women.
Comparative Effectiveness of Tobacco Control Measures
The comparative effectiveness of the simulated tobacco control
interventions among different cohorts is illustrated in Figures 3
and 4. Table 2 provides details of the modeled absolute and
percentage declines in myocardial infarction and stroke deaths
attributable to each intervention over the decade from 2013
through 2022.
The two most effective interventions were smoke-free legislation
and tobacco taxation. Smoke-free legislation would be anticipated
to avert approximately 0.7 million myocardial infarction deaths
(95% CI: 0.4 to 1.0 million, about 3.7% of myocardial infarction
deaths) and 0.4 million stroke deaths (95% CI: 0.3 to 0.6 million,
3.8%) over the decade. By comparison, a 300% increase in the
cigarette tax rate would be anticipated to avert approximately 1.0
million myocardial infarction deaths (95% CI: 0.8 to 1.1 million,
about 4.9% of myocardial infarction deaths) and 0.6 million stroke
deaths (95% CI: 0.5 to 0.7 million, 5.0%) over the decade. A
Figure 1. Overall mortality trend for myocardial infarctions in India over the period 2013–2022. ‘‘Meds’’ simulates the cumulative effects
of aspirin, antihypertensive drugs, and statins. ‘‘Tobacco control’’ refers to a combination of smoke-free legislation, brief cessation advice by clinicians,
a mass media campaign, a ban on advertising, and a 300% tax rate increase on both bidis and cigarettes with a cumulative impact equal to
12([12risk reduction from intervention A]6[12risk reduction from intervention B], etc.). ‘‘TC+meds’’ refers to the combination of all medications and
tobacco control measures, also assuming cumulative impact. MI, myocardial infarction.
doi:10.1371/journal.pmed.1001480.g001
Figure 2. Overall mortality trend for strokes in India over the period 2013–2022. ‘‘Meds’’ simulates the cumulative effects of aspirin,
antihypertensive drugs, and statins. ‘‘Tobacco control’’ refers to a combination of smoke-free legislation, brief cessation advice by clinicians, a mass
media campaign, a ban on advertising, and a 300% tax rate increase on both bidis and cigarettes with a cumulative impact equal to 12([12risk
reduction from intervention A]6[12risk reduction from intervention B], etc.). ‘‘TC+meds’’ refers to the combination of all medications and tobacco
control measures, also assuming cumulative impact.
doi:10.1371/journal.pmed.1001480.g002
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300% increase in the bidi tax rate was not as effective as the
cigarette tax increase; this bidi tax increase would avert
approximately 0.8 million myocardial infarction deaths (95% CI:
0.7 to 0.9, about 4.0% of myocardial infarction deaths) and 0.5
million stroke deaths (95% CI: 0.4 to 0.6 million, 4.0%) over the
decade. A 300% increase in both cigarette and bidi tax rates would
be anticipated to avert approximately 2.1 million myocardial
infarction deaths (95% CI: 1.8 to 2.4 million, about 8.8% of
myocardial infarction deaths) and 1.0 million stroke deaths (95%
CI: 0.9 to 1.2 million, 9.0%) over the decade.
The least effective population-level tobacco control interven-
tion, as shown in Table 1, was brief cessation advice by health
providers, which would be anticipated to avert approximately
60,000 myocardial infarction deaths (95% CI: 40,000 to 90,000,
Figure 3. Comparative effectiveness of alternative tobacco control and pharmacological interventions on future myocardial
infarction deaths, 2013–2022. 95% confidence intervals are displayed as error bars. MI, myocardial infarction; RM, rural men; RW, rural women;
UM, urban men; UW, urban women.
doi:10.1371/journal.pmed.1001480.g003
Figure 4. Comparative effectiveness of alternative tobacco control and pharmacological interventions on future stroke deaths,
2013–2022. 95% confidence intervals are displayed as error bars. RM, rural men; RW, rural women; UM, urban men; UW, urban women.
doi:10.1371/journal.pmed.1001480.g004
Tobacco and CVD in India
PLOS Medicine | www.plosmedicine.org 6 July 2013 | Volume 10 | Issue 7 | e1001480
about 0.3% of myocardial infarction deaths) and 40,000 stroke
deaths (95% CI: 30,000 to 60,000, about 0.3%) over the decade.
Nearly all of the tobacco control interventions affected urban
men more than rural men, and urban women more than rural
women. Between 28% and 35% of averted myocardial infarction
deaths were among urban men, 28% to 48% among rural men,
7% to 21% among urban women, and 16% to 19% among rural
women. Of the averted stroke deaths, 24% to 29% were among
urban men, 25% to 42% among rural men, 10% to 24% among
urban women, and 21% to 24% among rural women (see Figures 3
and 4 for breakdowns by intervention).
Sensitivity Analysis of Tax Rates
We varied the rate of taxation of cigarettes and bidis both
independently and together. An increase in the bidi tax rate by
800% would increase the number of myocardial infarctions
averted from 0.8 to 2.0 million (95% CI: 1.97 to 2.06 million,
10.1% decrease) and the number of strokes averted from 0.5 to 1.3
million (95% CI: 1.27 to 1.32 million, 10.4%). An increase in the
cigarette tax by 800% would similarly increase the number of
myocardial infarctions averted from 1.0 to 2.5 million (95% CI:
2.2 to 2.8 million, 12.5% decrease) and the number of strokes
averted from 0.6 to 1.6 million (95% CI: 1.4 to 1.8 million,
12.7%). Reducing the taxation rate to just a 50% increase above
current levels caused a linear proportional drop in effectiveness,
producing one-sixth the effect of the 300% tax increase.
Potential Synergy
Figures 5 and 6 illustrate the effects of different degrees of
synergy between combined interventions. If we assume that
tobacco control strategies that are combined will not have any
additive effects (e.g., only the most potent control measure will
have its effect exerted), then combining the five interventions (with
the tax rate increase set to our baseline level of a 300% increase)
would incorporate the passive smoking benefit reductions of
smoke-free tobacco legislation and the active smoking benefit
reductions of 300% increased tax rates on bidis and cigarettes.
This scenario would be anticipated to avert approximately 2.4
million myocardial infarction deaths (95% CI: 1.5 to 3.3 million,
12.2% of myocardial infarction deaths) and 1.5 million stroke
deaths (95% CI: 0.9 to 2.1 million, 12.5%) over the decade.
The estimated efficacy of the combined tobacco control
program increased if we assumed cumulative benefits from the
interventions (i.e., the effect of multiple measures is equal to
12[(12risk reduction from intervention A)6(12risk reduction
from intervention B)6(12risk reduction from intervention C)],
etc.), and increased further when we simulated a synergistic
interaction (such that their combination enhances the efficacy of
each individual intervention by 25%). However, as shown in
Table 2 and Figures 5 and 6, there was a high degree of
uncertainty in the simulations, given the compounded uncertainty
of each individual intervention’s impact. In the 25% synergy
scenario, the tobacco control package of the five interventions
would be anticipated to avert approximately 6.3 million myocar-
dial infarction deaths (95% CI: 5.4 to 7.2 million, about 31.6% of
myocardial infarction deaths) and 4.0 million stroke deaths (95%
CI: 3.4 to 4.6 million, 32.3%) over the decade.
Impact of Pharmacological Interventions
Figures 3 and 4 and Table 2 display results from our simulations
of pharmacological therapies compared with tobacco control
interventions. Statin therapy had the largest projected impact on













Tobacco control Smoke-free legislation 734,000 (487,000–981,000) 3.7 435,000 (289,000–581,000) 3.8
Brief cessation advice 64,000 (40,000–88,000) 0.3 41,000 (25,000–57,000) 0.3
Mass media 320,000 (233,000–407,000 ) 1.6 205,000 (149,000–261,000) 0.3
Advertising ban 384,000 (305,000–463,000) 1.9 246,000 (195,000–297,000) 2.0
300% bidi tax 787,000 (768,000–806,000) 4.0 507,000 (495,000–519,000) 4.0
300% cigarette tax 965,000 (841,000–1,089,000) 4.9 617,000 (538,000–696,000) 5.0
300% bidi and cigarette tax 2,114,000 (1,843,000–2,385,000) 8.8 1,021,000 (890,000–1,152,000) 9.0
Pharmacological Aspirin 232,000 (225,000–239,000) 1.1 79,000 (77,000–81,000) 0.5
Anti-hypertensives 241,000 (230,000–252,000) 1.1 234,000 (224,000–244,000) 1.6
Statin 307,000 (290,000–324,000) 1.4 44,000 (42,000–46,000) 0.3
Combinations All meds 769,000 (677,000–861,000) 3.5 852,000 (751,000–953,000) 5.8
All TC (no additive effects) 2,422,000 (1,501,000–3,343,000) 12.2 1,517,000 (940,000–2,094,000) 12.5
All TC (cumulative effects) 5,018,000 (4,097,000–5,939,000) 25.3 3,182,000 (2,598,000–3,766,000) 25.8
All TC (25% synergy) 6,272,000 (5,351,000–7,193,000) 31.6 3,978,000 (3,394,000–4,562,000) 32.3
All TC+all meds 5,954,000 (5,033,000–6,875,000) 30.0 3,736,000 (3,158,000–4,314,000) 30.3
‘‘All meds’’ assumes that the effects of aspirin, antihypertensive drugs, and statins are additive. ‘‘All TC’’ refers to a combination of smoke-free legislation, brief cessation
advice by clinicians, a mass media campaign, a ban on advertising, and a 300% tax rate increase on both bidis and cigarettes. ‘‘No additive effects’’ means that only the
impact of the most effective tobacco control intervention produces the resulting effectiveness of the tobacco control package. ‘‘Cumulative effects’’ assumes that a
combined package of tobacco control interventions would have an impact equal to 12([12risk reduction from intervention A]6[12risk reduction from intervention B],
etc.). ‘‘25% synergy’’ assumes that when the interventions are combined, the impact of each individual intervention is amplified by 25%.
MI, myocardial infarction; TC, tobacco control.
doi:10.1371/journal.pmed.1001480.t002
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myocardial infarction deaths among the medications (averting
1.4% of myocardial infarction deaths over the simulated period),
while antihypertensive therapy had the greatest impact on stroke
deaths (averting 1.6%).
If we assume cumulative benefits among the pharmacological
therapies, then having all of the therapies available would be
anticipated to avert approximately 0.8 million myocardial
infarction deaths (95% CI: 0.7 to 0.9 million, about 3.5% of
myocardial infarction deaths) and 0.9 million stroke deaths (95%
CI: 0.8 to 1.0 million, 5.8%) over the decade. This indicates that
the combination of medications was about as effective as the 300%
bidi tax rate increase alone in preventing myocardial infarction
deaths and slightly more effective than the 300% cigarette tax
increase alone in preventing stroke deaths, though the medication
combination is not as effective as the combination of 300% tax
increases on both cigarettes and bidis (Table 2). The combined
effects of all the pharmacological interventions were also smaller
than the effect of implementing smoke-free laws. Note that these
scenarios assume a slow rate of increase of access to pharmaco-
logical therapies.
The impact of medications was, however, only moderately
sensitive to the rate of diffusion in the population. If 80% coverage
were achieved by 10 y, then the combination of therapies
(assuming additive benefits between the medications) would be
anticipated to avert approximately 1.0 million myocardial
infarction deaths (95% CI: 0.9 to 1.2 million, about 4.7% of
myocardial infarction deaths) and 1.0 million stroke deaths (95%
CI: 0.9 to 1.1 million, 6.8%) over the decade. In this scenario, too,
the combination of medications would be less effective than the
300% tax rate increase on both bidis and cigarettes.
Combining Tobacco Control with Pharmacological
Interventions
Adding a tobacco control package (including smoke-free
legislation, brief cessation advice, a mass media campaign,
advertising ban, and 300% tax rate increase on both cigarettes
and bidis) to the combination of all of the pharmacological
interventions, assuming all interventions have cumulative effects,
we would anticipate averting approximately 6.0 million myocar-
dial infarction deaths (95% CI: 5.0 to 6.9 million, about 30.0% of
myocardial infarction deaths) and 3.7 million stroke deaths (95%
CI: 3.2 to 4.3 million, 30.3%) per year over the decade (Table 2).
This combination of additive tobacco control and all three types of
medications was slightly less powerful than the full tobacco control
package alone with the assumption that 25% synergy occurred
between the tobacco control interventions.
Figure 5. Impact of combining interventions on future myocardial infarction deaths, 2013–2022. Note the change in y-axis scale from
Figure 2. ‘‘All meds’’ assumes the effects of aspirin, antihypertensive drugs, and statins are cumulative. ‘‘All TC’’ refers to a combination of smoke-free
legislation, brief cessation advice by clinicians, a mass media campaign, a ban on advertising, and a 300% tax rate increase on both bidis and
cigarettes. ‘‘No additive effects’’ means that only the impact of the most effective tobacco control intervention produces the resulting effectiveness of
the tobacco control package. ‘‘Cumulative effects’’ assumes that a combined package of tobacco control interventions would have a cumulative
impact equal to 12([12risk reduction from intervention A]6[12risk reduction from intervention B], etc.). ‘‘25% synergy’’ assumes that when the
interventions are combined cumulatively, the impact of each individual intervention is amplified by 25%. 95% confidence intervals are displayed as
error bars. RM, rural men; RW, rural women; UM, urban men; UW, urban women.
doi:10.1371/journal.pmed.1001480.g005
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Impact among Different Age Groups
Without any new interventions, the largest burden of deaths
from myocardial infarctions and strokes would be expected to
accrue in the 60- to 69-y-old age group more than in any other age
cohort; this age group would experience 48% of myocardial
infarction deaths and 55% of stroke deaths. When tobacco control
measures are instituted, the greatest benefits similarly accrue in the
60- to 69-y-old age group, who make up 46% of averted
myocardial infarction deaths and 54% of averted stroke deaths
from any of the tobacco control interventions except smoke-free
legislation. None of the tobacco control interventions differed in
how they affected different age groups, except for smoke-free
legislation, which—because of differential exposure to secondhand
smoke among different age groups—had an increased benefit to
younger populations. Of the myocardial infarctions averted by
smoke-free legislation, 41% would be expected to accrue among
60- to 69-y-olds, and 12% would be averted in the 30- to 39-y-old
age group, as opposed to only 9% from any of the other
interventions. Of the strokes averted by smoke-free legislation,
50% would be expected to accrue among 60- to 69-y-olds, and
11% would be averted in the 30- to 39-y-old age group, as
opposed to only 8% from any of the other interventions. The
pharmacological interventions were most beneficial to the 60- to
69-y-old cohort; this age group accounted for 48% of the
myocardial infarction deaths averted by medicines and 55% of
the strokes averted by medicines.
Speed of Implementation
Our baseline simulation was constructed to reflect the speed of
implementation observed in other developing countries [12]. If
tobacco control measures are delayed such that they are
introduced at a linear rate from 0% to 80% coverage over 5 y,
and thereafter remain at a steady state of 80% coverage, their
impact over the next decade could be lowered by approximately
60% from the above estimates (95% CI: 45%–70%). The slower
rate of implementation would result in a shift in the gender
distribution of deaths as well. Because trends in death disfavor
males, of the total deaths taking place over the next decade, the
proportion of deaths made up by males would be expected to be
13 percentage points higher than in the baseline scenario of 64%
male deaths.
Discussion
Substantial evidence links tobacco use to CVD, yet tobacco use
in India and several other LMICs is on the rise [6]. This worsening
Figure 6. Impact of combining interventions on future stroke deaths, 2013–2022. Note the change in y-axis scale from Figure 2. ‘‘All meds’’
assumes the effects of aspirin, antihypertensive drugs, and statins are cumulative. ‘‘All TC’’ refers to a combination of smoke-free legislation, brief
cessation advice by clinicians, a mass media campaign, a ban on advertising, and a 300% tax rate increase on both bidis and cigarettes. ‘‘No additive
effects’’ means that only the impact of the most effective tobacco control intervention produces the resulting effectiveness of the tobacco control
package. ‘‘Cumulative effects’’ assumes that a combined package of tobacco control interventions would have a cumulative impact equal to
12([12risk reduction from intervention A]6[12risk reduction from intervention B], etc.). ‘‘25% synergy’’ assumes that when the interventions are
combined cumulatively, the impact of each individual intervention is amplified by 25%. 95% confidence intervals are displayed as error bars. RM, rural
men; RW, rural women; UM, urban men; UW, urban women.
doi:10.1371/journal.pmed.1001480.g006
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trend led the UN High Level Meeting on Prevention and Control
of Non-Communicable Diseases to recommend that countries
accelerate implementation of the FCTC. Our findings indicate
that full implementation of key FCTC articles in India would yield
substantial reductions in mortality from myocardial infarctions
and stroke, despite projected increases in other risk factors for
CVD such as hypertension and diabetes. Far from achieving
‘‘diminishing returns,’’ vigorous implementation of these tobacco
control policies would be expected to avert 25% of all predicted
CVD deaths, equivalent to over 9 million averted deaths, over the
decade 2013 and 2022 under a reasonable set of modeling
assumptions.
Furthermore, the population-level benefits of implementing
strong tobacco control policies were five times greater than a
similarly aggressive program to implement pharmacological
interventions (Figure 3), assuming that India’s implementation of
pharmacological therapy is no faster than in high-income nations
like the UK. However, critically, we would anticipate additive
benefits of implementing pharmacological interventions concur-
rently with strong tobacco control policies: the combined package
of both pharmacological and tobacco control interventions would
not be redundant, and could avert nearly a third of cardiovascular
and cerebrovascular mortality over the next decade by tackling
multiple risk factors for myocardial infarctions and strokes.
Among the interventions we simulated, smoke-free legislation
and tax increases on both cigarettes and bidis were the most
effective at the population level. Smoke-free legislation, an
advertising ban, and a mass media campaign had wide confidence
intervals because their degree of population effectiveness was
subject to the degree of effective enforcement.
We used, to our knowledge for the first time, population-
representative data to represent the co-morbid risks of CVD
among both urban and rural populations in India, and among
both men and women in multiple agegroups. We found that nearly
all sectors of Indian society were likely to benefit from both
tobacco control and pharmacological therapies. However, the
populations benefiting most were urban males and persons in the
60- to 69-y-old age category. This is due to the higher baseline
prevalence of co-morbid risk factors among urban males and this
older age group; hence, these populations achieve greater risk
reduction from the simulated interventions.
Limitations
Projections from mathematical models such as this one are
limited by assumptions and uncertainties inherent to the exercise
of mathematical modeling. Models are useful at a policy level for
comparing different population-wide interventions because it is,
for practical purposes, challenging to institute large-scale random-
ized trials of such population-level interventions for comparing the
potential future implications of such interventions when several
demographic and biological factors come into play. We modeled
the effects of tobacco control in accordance with published
international data and assumed that the Indian population would
respond to tobacco control measures similarly to other popula-
tions. While this model was validated against independent Global
Burden of Disease estimates, such estimates are not themselves a
real population registry, but rather are largely imputed data from
sporadic surveys; hence, this model cannot be thought of as
calibrated or validated retrospectively against a real population. A
potential amendment to this problem is prospective validation and
further refinement of this model against emerging datasets that will
provide some further information on risks, such as the WHO
Study on Global Ageing and Adult Health [11].
These estimates serve as an important template for other
LMICs looking for effective policies to stem the growing tide of
noncommunicable diseases, as India’s tobacco use, as well as the
prevalence of other major risk factors, is thought to be
representative of many other middle-income nations [11]. We
simulated several alternative additive or multiplicative effects of
different tobacco control approaches, but we do not yet know
whether some interventions are more effective in certain age
groups or in one gender over the other—for example, there are
potentially more significant declines in smoking when interven-
tions target youth [27]. We also simulated the impact of
pharmacological therapy using optimistic medication adherence
rates, but if true adherence rates are lower, this would further
reinforce our findings of relatively higher and faster impact from
tobacco control interventions. Furthermore, we did not simulate
the cost-effectiveness of the various interventions, as the cost
estimates are currently inconsistent, in part because of rapidly
changing prices of drugs and the unclear administrative costs of
many of the control measures described, particularly in rural zones
[28–30]. Nevertheless, prior models based on reasonable estimates
of cost have found tobacco control measures and pharmacological
interventions to be highly cost-effective in LMICs [15,25]. It is
nevertheless notable that smoke-free measures and tax increases
come with relatively low administrative costs, unlike pharmaco-
logical interventions.
Our estimates of the risk factor prevalence and mortality rates
among cohorts defined by age, gender, and location were based on
estimates from the WHO, and there is uncertainty about these
estimates as they are subject to surveillance bias that may reduce
the estimated mortality rates of women, rural populations, or the
isolated elderly; however, sensitivity and uncertainty analyses
around our input parameters suggest that our primary findings are
not changed despite wide variations in these data estimates. We
modeled only the short-term effects of reduced tobacco use on
CVD. It has been suggested that lack of smoke exposure over
longer terms will produce greater benefits to cardiovascular health
[31]; such an assumption would result in larger reductions in CVD
from tobacco control than we present here. It is also important to
note, given the smoking options in India, that an increase in the
tax rate on just cigarettes, but not bidis, also may lead to increased
smoking of bidis, which could reduce the beneficial impact of the
cigarette tax. Furthermore, the data we have available on India’s
specific CVD mortality rates and risk factor prevalence levels do
not explicitly disaggregate the population by socioeconomic status,
only by age, gender, and urban/rural location. Understanding
socioeconomic differences should be a high priority for future
research. Finally, we did not model many other emerging
interventions that could affect the risk factors simulated here,
such as nutritional interventions.
Conclusion
Given the complexities of India’s tobacco and CVD epidemics,
it is important to understand how heterogeneities within the large
Indian population may affect both the risk of disease as well as the
impact of various policy and health care interventions. In this
study, we provide to our knowledge the first model that
incorporates population-representative data from India disaggre-
gated by age, gender, and location for all of the major CVD risk
factors as well as for specific types of tobacco use. Prior models
have either used ‘‘average’’ Indian or regional disease rates, have
not captured various types of tobacco use other than smoking, or
have not incorporated the multiple risk factors affecting CVD in
addition to tobacco use. This means that, for the first time, we can
study some health disparities in CVD and in tobacco use within
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the large and varied Indian population, as well as heterogeneity in
the impact of proposed interventions. These results provide clear
justification for India’s Ministry of Health and Family Welfare to
engage in greater enforcement of the FCTC and the Indian
legislation that enacts the FCTC in the country, the Cigarettes and
Other Tobacco Products Act.
Our simulations suggest that the implementation of recom-
mended tobacco control interventions in India would yield
substantial and rapid health benefits, but those benefits may
accumulate most among males, urban dwellers, and older adults.
Effective implementation of FCTC provisions remains a major
challenge in India. At present, smoke-free legislation in India is not
comprehensive and is poorly enforced [12]. There is little indication
that brief cessation advice is routinely administered, and additional
resources may be required to strengthen implementation. Tobacco
taxes in India would also need to be substantially increased and
harmonized between different tobacco products to comply with
WHO recommendations, and achieve desired population-level
disease reductions [14,15]. Cigarettes are currently taxed according
to their physical length in India, meaning that uniform tax increases
will encourage product substitution unless large price differentials
between products are addressed.
Optimizing preventive interventions for CVD remains a
significant challenge for developing countries like India. Our
model demonstrates synergies between tobacco control and
pharmacological therapies for key CVD risk factors. It does not,
however, support the idea that enhanced prevalence of key risk
factors renders diminished results from tobacco control interven-
tions. Rather, policymakers should take note that fuller and faster
implementation of existing FCTC provisions would likely be a
substantial boon to efforts to reduce CVD mortality in India and
other LMICs.
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Editors’ Summary
Background. Cardiovascular diseases (CVDs) are conditions
that affect the heart and/or the circulation. In coronary heart
disease, for example, narrowing of the heart’s blood vessels
by fatty deposits slows the blood supply to the heart and
may eventually cause a heart attack (myocardial infarction).
Stroke, by contrast, is a CVD in which the blood supply to the
brain is interrupted. CVD has been a major cause of illness
and death in high-income countries for many years, but the
burden of CVD is now rapidly rising in low- and middle-
income countries. Indeed, worldwide, three-quarters of all
deaths from heart disease and stroke occur in low- and
middle-income countries. Smoking, high blood pressure
(hypertension), high blood cholesterol (hyperlipidemia),
diabetes, obesity, and physical inactivity all increase an
individual’s risk of developing CVD. Prevention strategies and
treatments for CVD include lifestyle changes (for example,
smoking cessation) and taking drugs that lower blood
pressure (antihypertensive drugs) or blood cholesterol levels
(statins) or thin the blood (aspirin).
Why Was This Study Done? Because tobacco use is a key
risk factor for CVD and for several other noncommunicable
diseases, the World Health Organization has developed an
international instrument for tobacco control called the
Framework Convention on Tobacco Control (FCTC). Parties
to the FCTC (currently 176 countries) agree to implement a
set of core tobacco control provisions including legislation to
ban tobacco advertising and to increase tobacco taxes. But
will tobacco control measures reduce the burden of CVD
effectively in low- and middle-income countries as other risk
factors for CVD are becoming more common? In this
mathematical modeling study, the researchers investigated
this question by simulating the effects of tobacco control
measures and pharmacological strategies for preventing
CVD on CVD deaths in India. Notably, many of the core FCTC
provisions remain poorly implemented or unenforced in
India even though it became a party to the convention in
2005. Moreover, experts predict that, over the next decade,
this middle-income country will contribute more than any
other nation to the global increase in CVD deaths.
What Did the Researchers Do and Find? The researchers
developed a microsimulation model (a computer model that
operates at the level of individuals) to quantify the likely
effects of various tobacco control measures and pharmaco-
logical therapies on deaths from myocardial infarction and
stroke in India between 2013 and 2022. They incorporated
population-representative data from India on risk factors that
affect myocardial infarction and stroke mortality and on
tobacco use and exposure to secondhand smoke into their
model. They then simulated the effects of five tobacco
control measures—smoke-free legislation, tobacco taxation,
provision of brief cessation advice by health care providers,
mass media campaigns, and advertising bans—and in-
creased access to aspirin, antihypertensive drugs, and statins
on deaths from myocardial infarction and stroke. Smoke-free
legislation and tobacco taxation are likely to be the most
effective strategies for reducing myocardial infarction and
stroke deaths over the next decade, according to the model,
and the effects of these strategies are likely to be
substantially larger than those achieved by drug therapies
under current health system conditions. If the effects of
smoke-free legislation and tobacco taxation are additive, the
model predicts that these two measures alone could avert
about 9 million deaths, that is, a quarter of the expected
deaths from myocardial infarction and stroke in India over
the next 10 years, and that a combination of tobacco control
policies and pharmacological interventions could avert up to
a third of these deaths.
What Do These Findings Mean? These findings suggest
that the implementation of smoke-free laws and the
introduction of increased tobacco taxes in India would yield
substantial and rapid health benefits by averting future CVD
deaths. The accuracy of these findings is likely to be affected
by the many assumptions included in the mathematical
model and by the quality of the data fed into it. Importantly,
however, these finding suggest that, despite the rise in other
CVD risk factors such as hypertension and hyperlipidemia,
tobacco control is likely to be a highly effective strategy for
the reduction of CVD deaths over the next decade in India
and probably in other low- and middle-income countries.
Policymakers in these countries should, therefore, work
towards fuller and faster implementation of the core FCTC
provisions to boost their efforts to reduce deaths from CVD.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001480.
N The American Heart Association provides information on
all aspects of cardiovascular disease; its website includes
personal stories about heart attacks and stroke
N The US Centers for Disease Control and Prevention has
information on heart disease and on stroke (in English and
Spanish
N The UK National Health Service Choices website provides
information about cardiovascular disease and stroke
N MedlinePlus provides links to other sources of
information on heart diseases, vascular diseases, and
stroke (in English and Spanish)
N The World Health Organization provides information (in
several languages) about the dangers of tobacco, about
the Framework Convention on Tobacco Control, and about
noncommunicable diseases; its Global Noncommunicable
Disease Network (NCDnet) aims to help low- and middle-
income countries reduce illness and death caused by CVD
and other noncommunicable diseases
N SmokeFree, a website provided by the UK National Health
Service, offers advice on quitting smoking and includes
personal stories from people who have stopped smoking
N Smokefree.gov, supported by the US National Cancer
Institute and other US agencies, offers online tools and
resources to help people quit smoking
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